Physician profile
James E Budge
NPI 1013918069
$1,358.15
in general payments reported to CMS, 2019-2025
10 companies · $668 in 2025
The $668 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $37.23 · 2021: $43.13 · 2023: $173 · 2024: $311 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $564.51 | 2023-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $247.78 | 2020-2025 | Total30, Precision7 |
| Coopervision INC. | $160.38 | 2019-2025 | Clariti Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $109.60 | 2023-2025 | Acuvue |
| Shire North American Group INC | $97.86 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $86.38 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $46.36 | 2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $19.43 | 2021 | |
| Ani Pharmaceuticals, INC. | $14.72 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Budge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.